Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
autologous dendritic cells + natural killer cells (National Taiwan University)
- Development stage
- Unknown
- Lead developer
- National Taiwan University Clinical Trial Center
- Modality
- Dendritic Cell Vaccines → Immune Effector Cells → Other Cell Types → Cell Therapies, CAR-NK Cells → Other Engineered Cells → Adoptive Cell Transfer → Cell Therapies, Lymphokine-Activated Killer Cells → Native Immune Cells → Adoptive Cell Transfer → Cell Therapies
- Administration
- Intravenous, Intralymphatic
01
Overview
This experimental cell therapy combination consists of autologous dendritic cells (DCs) and natural killer (NK) cells cultured in vitro. Developed by the National Taiwan University Clinical Trial Center, the therapy is designed to treat advanced or recurrent non-small cell lung cancer (NSCLC). The dendritic cells are administered via axillary lymph node injection to prime the adaptive immune system and activate T-cell responses against tumor antigens. Simultaneously, the autologous natural killer cells are administered intravenously to provide direct, innate cytotoxic activity against tumor cells. The treatment approach aims to leverage both the antigen-presenting capabilities of DCs and the direct tumor-killing potential of NK cells to overcome immune evasion in lung cancer patients who have failed prior systemic therapies.
- Other names
- Autologous DC and NK cellsIn vitro culture of autologous dendritic and natural killer cells
Beyond the preview
Go deeper on autologous dendritic cells + natural killer cells (National Taiwan University).
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on autologous dendritic cells + natural killer cells (National Taiwan University).